secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001437749-24-025179
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros Q2 net loss $56M ($0.97/sh) vs $37M; restructures debt with $67M term loan
--------------------------------------------------------------------------------

- Net loss $56.0M ($0.97/sh) vs $37.3M ($0.59); includes $17.6M narsoplimab charge, $21.2M debt repurchase.
- Entered $67.1M secured term loan with Athyrium/Highbridge; repurchased $118.1M of 5.25% 2026 notes at ~25% discount.
- Cash and investments $158.9M at June 30; OMIDRIA royalties $10.9M on Rayner net sales $36.4M.
- FDA meeting scheduled for narsoplimab BLA resubmission in TA-TMA; Phase 3 for zaltenibart in PNH on track for late 2024.
- Zaltenibart Phase 2 data: mean hemoglobin improvement 3.27 g/dL; 10/12 patients advanced to monotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000143774924025179/0001437749-24-025179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000143774924025179/omer20240523_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-025179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer